Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to examine the endometrial, ovarian, and breast safety of bazedoxifene, a novel selective estrogen-receptor modulator, in postmenopausal women at risk for osteoporosis. METHODS: Healthy postmenopausal women (N = 1,583; mean age, 57.6 y) with lumbar spine or femoral neck bone mineral density T scores between -1 and -2.5 and/or other clinical risk factors for osteoporosis were enrolled in a 24-month, phase 3, randomized, double-blind, placebo- and active-controlled trial. They received daily treatment with bazedoxifene 10, 20, or 40 mg; placebo; or raloxifene 60 mg. Reproductive safety assessments included periodic transvaginal ultrasound measurements of endometrial thickness, ovarian volume, and presence of ovarian cysts; periodic endometrial biopsies; and adverse event reporting. RESULTS: Bazedoxifene was not associated with a significant change from baseline in mean endometrial thickness at month 24. The percentage of participants with a change from baseline in endometrial thickness or endometrial thickness greater than 5 mm at month 24 was similar among groups. There was no consensus diagnosis of endometrial hyperplasia or malignancy in the bazedoxifene or raloxifene groups; the rates of other histologic findings, including endometrial polyps, were low (<5%) and similar among groups. No significant between-group differences were found in the change from baseline in ovarian volume, number or size of ovarian cysts, or incidence of ovarian cancer. Reports of breast pain (<4%) and breast cancer (<1%) were low and evenly distributed among groups. CONCLUSION: A favorable endometrial, ovarian, and breast safety profile was found after 2 years of treatment with bazedoxifene in healthy, recently postmenopausal women at risk for osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Cited by
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Kulak, J., Fischer, C., Komm, B., & Taylor, H. S. (2011) · Endocrinology · doi:10.1210/en.2010-1010 · Cited by 112
Metadata
- Authors
- Pinkerton, J. V., Archer, D. F., Utian, W. H., Menegoci, J. C., Levine, A. B., Chines, A. A., & Constantine, G. D.
- Venue
- Menopause
- Published
- 2009-11
- Volume
- 16
- Issue
- 6
- Pages
- 1102-1108
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W2032497885
- Cited by
- 81
- References
- 1
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. https://app.cochat.ai/papers/10.1097/gme.0b013e3181a816be
- The paper
- Pinkerton, J. V., Archer, D. F., Utian, W. H., Menegoci, J. C., Levine, A. B., Chines, A. A., & Constantine, G. D. (2009). Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause. https://doi.org/10.1097/gme.0b013e3181a816be
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.